In a recent study, sacituzumab govitecan, an ADC comprising an antibody targeting the human trophoblast cell surface antigen 2 (TROP-2), extended progression-free and overall survival compared to single-agent chemotherapy among patients with metastatic triple-negative breast cancer [10]. This evidence concerns the gene TACSTD2 and triple-negative breast carcinoma.